secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2026-09-17T19:37:59+00:00
Accession:  0001213900-26-100929
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

ORMP shareholders re-elect board, approve incentive plan increase and triennial say-on-pay
--------------------------------------------------------------------------------

- All six directors re-elected; favorable votes ranged from 11.57M (Shapiro) to 13.70M (N. Kidron).
- Ratification of Kesselman & Kesselman (PwC member) as 2026 fiscal year auditor passed: 22.24M for, 2.72M against.
- 2019 Stock Incentive Plan amendment approved, increasing authorized shares by 3M to 12.5M total.
- Say-on-pay approved (13.01M for, 4.39M against); stockholders selected every-three-years frequency (11.38M for).
- Board adopted triennial say-on-pay votes until the next required frequency vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390026100929/0001213900-26-100929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390026100929/ea0305871-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-100929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer